PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer

Breast cancer is a heterogeneous disease, manifesting in a broad differentiation in phenotypes and morphologic profiles, resulting in variable clinical behavior. Between 10 and 20% of all breast cancers are triple negative. Triple-negative breast cancer (TNBC) lacks the expression of human epidermal...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacokinetics 2018-04, Vol.57 (4), p.427-437
Hauptverfasser:	Geenen, Jill J. J., Linn, Sabine C., Beijnen, Jos H., Schellens, Jan H. M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers Biomarkers, Tumor - genetics BRCA1 Protein - genetics BRCA2 Protein - genetics Breast cancer Cancer therapies Cell cycle Chemotherapy Clinical trials Deoxyribonucleic acid DNA Drug Resistance, Neoplasm Epidermal growth factor Female Genetic Predisposition to Disease Genotype & phenotype Homologous Recombination Humans Internal Medicine Kinases Medical prognosis Medicine Medicine & Public Health Mutation Ovarian cancer Pharmacology/Toxicology Pharmacotherapy Phenotype Poly(ADP-ribose) Polymerase Inhibitors - adverse effects Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Review Article Targeted cancer therapy Treatment Outcome Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - enzymology Triple Negative Breast Neoplasms - genetics Triple Negative Breast Neoplasms - pathology Tumors Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!